title: Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: part I.
abstract: Transcatheter endovascular procedures are increasingly used to treat symptomatic peripheral atherosclerosis. This two-part review identifies the existing evidence supportive of the application of transcatheter treatments for peripheral atherosclerotic lesions. The first part addresses the treatment of obstructive lesions that cause limb claudication and critical ischemia, renovascular hypertension and azotemia, and mesenteric ischemia. Studies were identified via a search of MEDLINE (January 1993 through April 1999) and reference lists of identified articles. When multicenter prospective randomized trials or other high-quality studies were unavailable, a preference was given to studies with at least 50 patients per treated group and a minimum mean follow-up duration of 6 months. Data presented in tables are proportionally weighted averages from included studies. For each application, the authors assessed the quality of evidence (QOE; efficacy, safety, and, where available, cost-effectiveness) and made recommendations with appropriate caveats. There is higher QOE supporting the more established treatments such as lower limb percutaneous transluminal angioplasty (PTA) with stent placement and thrombolysis. Treatments such as renal artery PTA and stent placement and mesenteric and brachiocephalic PTA are in wide use, but high QOE supporting general application is lacking. Blanket recommendations based on established efficacy and cost-effectiveness cannot be made. However, the use of transcatheter therapies can be supported in specific circumstances based on an expected reduction in procedure-related morbidity and/or mortality rates. It is hoped that the identification of deficiencies in the literature will inform and inspire critically needed research in this area.
authors.affiliation: Department of Radiology, Weill Medical College, Cornell University, New York, USA. krk2002@mail.med.cornell.edu
authors.forename: K
authors.initials: K
authors.lastname: Kandarpa
authors.forename: G J
authors.initials: GJ
authors.lastname: Becker
authors.forename: M G
authors.initials: MG
authors.lastname: Hunink
authors.forename: T O
authors.initials: TO
authors.lastname: McNamara
authors.forename: J H
authors.initials: JH
authors.lastname: Rundback
authors.forename: D W
authors.initials: DW
authors.lastname: Trost
authors.forename: T A
authors.initials: TA
authors.lastname: Sos
authors.forename: M R
authors.initials: MR
authors.lastname: Poplausky
authors.forename: C P
authors.initials: CP
authors.lastname: Semba
authors.forename: W J
authors.initials: WJ
authors.lastname: Landow
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D001161:Arteriosclerosis / Q000188:drug therapy / Q000628:therapy*; D002406:Catheterization, Peripheral; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D006978:Hypertension, Renovascular / Q000628:therapy; D007676:Kidney Failure, Chronic / Q000628:therapy; D015607:Stents
chemical_list: D005343:Fibrinolytic Agents